The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Adjuvant Chemotherapy for Stage II Colon Cancer With Poor Prognostic Features
Open accessAbstract
Purpose: Adjuvant chemotherapy is typically considered for patients with stage II colon cancer characterized by poor prognostic features, including obstruction, perforation, emergent admission, T4 stage, resection of fewer than 12 lymph nodes, and poor histology. Despite frequent use, the survival advantage conferred on patients with stage II disease by chemotherapy is yet unproven. We sought to determine the overall survival benefit of chemotherapy among patients with stage II colon cancer having poor prognostic features. Patients and Methods: A total of 43,032 Medicare beneficiaries who underwent colectomy for stage II and III primary colon adenocarcinoma diagnosed from 1992 to 2005 were identified from the Surveillance, Epidemiology, and End Results (SEER) –Medicare database. χ 2 and two-way analysis of variance were used to assess differences in patient- and disease-related characteristics. Five-year overall survival was examined using Kaplan-Meier survival analysis and Cox proportional hazards regression with propensity score weighting. Results: Of the 24,847 patients with stage II cancer, 75% had one or more poor prognostic features. Adjuvant chemotherapy was received by 20% of patients with stage II disease and 57% of patients with stage III disease. After adjustment, 5-year survival benefit from chemotherapy was observed only for patients with stage III disease (hazard ratio[HR], 0.64; 95% CI, 0.60 to 0.67). No survival benefit was observed for patients with stage II cancer with no poor prognostic features (HR, 1.02; 95% CI, 0.84 to 1.25) or stage II cancer with any poor prognostic features (HR, 1.03; 95% CI, 0.94 to 1.13). Conclusion: Among Medicare patients identified with stage II colon cancer, either with or without poor prognostic features, adjuvant chemotherapy did not substantially improve overall survival. This lack of benefit must be considered in treatment decisions for similar older adults with colon cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Estimating Causal Effects from Large Data Sets Using Propensity Scores
Rubin, D. B. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-8_part_2-199710151-00064 · Cited by 2,877
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Weisenberger, D. J., Siegmund, K. D., Campan, M., Young, J., Long, T. I., Faasse, M. A., Kang, G. H., Widschwendter, M., Weener, D., Buchanan, D., et al. (2006) · Nature Genetics · doi:10.1038/ng1834 · Cited by 1,990
Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · PubMed · doi:10.1097/01.mlr.0000020942.47004.03 · Cited by 1,714
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
QUASAR Collaborative Group (2007) · The Lancet · doi:10.1016/s0140-6736(07)61866-2 · Cited by 1,437
Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J., McAllister, P., Van Cutsem, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.063 · Cited by 1,430
Le Voyer, T. E., Sigurdson, E. R., Hanlon, A. L., Mayer, R. J., Macdonald, J. S., Catalano, P. J., & Haller, D. G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.062 · Cited by 1,149
Adjuvant Therapy for Patients With Colon and Rectal Cancer
(1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450110090034 · Cited by 1,086
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
(1995) · The Lancet · doi:10.1016/s0140-6736(95)90696-7 · Cited by 1,066
Rubin, D. B. (2007) · Statistics in Medicine · doi:10.1002/sim.2739 · Cited by 1,047
Gill, S., Loprinzi, C. L., Sargent, D. J., Thomé, S. D., Alberts, S. R., Haller, D. G., Benedetti, J., Francini, G., Shepherd, L. E., Francois Seitz, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.059 · Cited by 1,021
Warren, J. L., Klabunde, C. N., Schrag, D., Bach, P. B., & Riley, G. F. (2002) · Medical Care · doi:10.1097/00005650-200208001-00002 · Cited by 772
POTOSKY, A. L., RILEY, G. F., LUBITZ, J. D., MENTNECH, R. M., & KESSLER, L. G. (1993) · Medical Care · doi:10.1097/00005650-199308000-00006 · Cited by 694
Wolmark, N., Rockette, H., Fisher, B., Wickerham, D. L., Redmond, C., Fisher, E. R., Jones, J., Mamounas, E. P., Ore, L., & Petrelli, N. J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1879 · Cited by 689
Sargent, D., Sobrero, A., Grothey, A., O'Connell, M. J., Buyse, M., Andre, T., Zheng, Y., Green, E., Labianca, R., O'Callaghan, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5362 · Cited by 666
Samowitz, W. S., Albertsen, H., Herrick, J., Levin, T. R., Sweeney, C., Murtaugh, M. A., Wolff, R. K., & Slattery, M. L. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.020 · Cited by 577
Mamounas, E., Wieand, S., Wolmark, N., Bear, H. D., Atkins, J. N., Song, K., Jones, J., & Rockette, H. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1349 · Cited by 531
Wolmark, N., Rockette, H., Mamounas, E., Jones, J., Wieand, S., Wickerham, D. L., Bear, H. D., Atkins, J. N., Dimitrov, N. V., Glass, A. G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3553 · Cited by 493
Efficacy of Adjuvant Fluorouracil and Folinic Acid in B2 Colon Cancer
(1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1356 · Cited by 444
Kim, G. P., Colangelo, L. H., Wieand, H. S., Paik, S., Kirsch, I. R., Wolmark, N., & Allegra, C. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.8172 · Cited by 342
Using diagnoses to describe populations and predict costs.
Ash, A. S., Ellis, R. P., Pope, G. C., Ayanian, J. Z., Bates, D. W., Burstin, H. R., Iezzoni, L. I., MacKay, E., & Yu, W. (2000) · PubMed Central · Cited by 299
Identification of Patients with High-Risk Stage II Colon Cancer for Adjuvant Therapy
Quah, H.-M., Chou, J. F., Gonen, M., Shia, J., Schrag, D., Landmann, R. G., Guillem, J. G., Paty, P. B., Temple, L. K., Wong, W. D., et al. (2008) · Diseases of the Colon & Rectum · doi:10.1007/s10350-008-9246-z · Cited by 255
Adjuvant Chemotherapy Use for Medicare Beneficiaries With Stage II Colon Cancer
Schrag, D., Rifas-Shiman, S., Saltz, L., Bach, P. B., & Begg, C. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.084 · Cited by 249
Readmission After Colectomy for Cancer Predicts One-Year Mortality
Greenblatt, D. Y., Weber, S. M., O'Connor, E. S., LoConte, N. K., Liou, J.-I., & Smith, M. A. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181d3d27c · Cited by 212
Self-citationContinued Rightward Shift of Colorectal Cancer
Cucino, C., Buchner, A. M., & Sonnenberg, A. (2002) · Diseases of the Colon & Rectum · doi:10.1007/s10350-004-6356-0 · Cited by 160
Completion of therapy by Medicare patients with stage III colon cancer
Dobie, S. A., Baldwin, L.-M., Dominitz, J. A., Matthews, B., Billingsley, K., & Barlow, W. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj159 · Cited by 150
Wilkinson, N. W., Yothers, G., Lopa, S., Costantino, J. P., Petrelli, N. J., & Wolmark, N. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0881-y · Cited by 143
Saltzstein, S. L., & Behling, C. A. (2007) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000225550.26751.6a · Cited by 113
Should Dukes' B patients receive adjuvant therapy? A statistical perspective
Buyse, M. E., & Piedbois, P. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90247-7 · Cited by 109
Clinical implications of microsatellite instability in sporadic colon cancers
Sinicrope, F. A., & Sargent, D. J. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32832c94bd · Cited by 91
FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer
Sharif, S., O’Connell, M. J., Yothers, G., Lopa, S., & Wolmark, N. (2008) · Cancer Investigation · doi:10.1080/07357900802132550 · Cited by 83
Adjuvant Chemotherapy After Resection in Elderly Medicare and Medicaid Patients With Colon Cancer
Bradley, C. J. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2007.82 · Cited by 75
Zuckerman, I. H., Rapp, T., Onukwugha, E., Davidoff, A. J., Choti, M. A., Gardner, J., Seal, B. S., & Mullins, C. D. (2009) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2009.02355.x · Cited by 62
D’Agostino (1998) · doi:10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b
Cited by
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492
Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
Tie, J., Cohen, J. D., Lahouel, K., Lo, S. N., Wang, Y., Kosmider, S., Wong, R., Shapiro, J., Lee, M., Harris, S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200075 · Cited by 1,091
Zhang, J.-X., Song, W., Chen, Z.-H., Wei, J.-H., Liao, Y.-J., Lei, J., Hu, M., Chen, G.-Z., Liao, B., Lu, J., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70491-1 · Cited by 544
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
Kotani, D., Oki, E., Nakamura, Y., Yukami, H., Mishima, S., Bando, H., Shirasu, H., Yamazaki, K., Watanabe, J., Kotaka, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02115-4 · Cited by 526
Metadata
- Authors
- O'Connor, E. S., Greenblatt, D. Y., LoConte, N. K., Gangnon, R. E., Liou, J.-I., Heise, C. P., & Smith, M. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-09-01
- Volume
- 29
- Issue
- 25
- Pages
- 3381-3388
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2105915644
- Cited by
- 451
- References
- 39
- FWCI
- 13.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.